^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-2 stimulant

    Related drugs:
    5d
    Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors. (PubMed, J Immunother Cancer)
    CA-induced immune pharmacodynamic effects in peripheral blood and in the tumor microenvironment without preferential Treg cell activation in patients with metastatic/unresectable CEA+ solid tumors.
    P1 data • Journal • PD(L)-1 Biomarker • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • CEACAM5 (CEA Cell Adhesion Molecule 5) • IL2RA (Interleukin 2 receptor, alpha) • IL2 (Interleukin 2) • CD14 (CD14 Molecule)
    |
    cergutuzumab amunaleukin (RG7813)
    6d
    Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=48, Not yet recruiting, Ruijin Hospital
    New P1/2 trial
    7d
    Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL (clinicaltrials.gov)
    P1/2, N=30, Suspended, Masonic Cancer Center, University of Minnesota | Trial completion date: Dec 2025 --> Dec 2026 | Recruiting --> Suspended | Trial primary completion date: Dec 2025 --> Sep 2026
    Trial completion date • Trial suspension • Trial primary completion date
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    LDH elevation
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Lymphir (denileukin diftitox-cxdl)
    7d
    Theratri: A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors (clinicaltrials.gov)
    P1, N=56, Recruiting, Philogen S.p.A. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    FAP (Fibroblast activation protein, alpha)
    |
    darleukin (L19IL2)
    13d
    ACT: Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, AgonOx, Inc. | Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: May 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    BRAF (B-raf proto-oncogene) • CD8 (cluster of differentiation 8)
    |
    AGX-148
    13d
    Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Zhejiang Cancer Hospital
    New P2 trial
    |
    capecitabine • oxaliplatin
    28d
    STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma (clinicaltrials.gov)
    P1, N=0, Withdrawn, City of Hope Medical Center | N=12 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    30d
    KEYNOTE-E46: Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, TILT Biotherapeutics Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • igrelimogene litadenorepvec (TILT-123)
    1m
    Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis (clinicaltrials.gov)
    P1, N=15, Recruiting, Mayo Clinic | Trial completion date: Jan 2026 --> Apr 2030 | Trial primary completion date: Jan 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • oxaliplatin • leucovorin calcium • Proleukin (aldesleukin) • fluorouracil topical • ABP 206 (nivolumab biosimilar)
    1m
    A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P2 trial
    1m
    A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body (clinicaltrials.gov)
    P1/2, N=240, Recruiting, Regeneron Pharmaceuticals | N=150 --> 240
    Enrollment change • First-in-human
    |
    Libtayo (cemiplimab-rwlc)
    1m
    HAMMER: A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) (clinicaltrials.gov)
    P1/2, N=175, Terminated, Synthorx, Inc, a Sanofi company | N=250 --> 175 | Active, not recruiting --> Terminated; The study was terminated as per Sponsor decision. The decision was not related to any safety concerns.
    Enrollment change • Trial termination
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • pegenzileukin (SAR444245)